Benzinga··Vandana SinghBig Pharma Circles Inhibrx Cancer Assets in $9B Spin-Off Deal
Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.
JNJMRKPFELLYSNY+2biotechclinical trials